Nasal Alzheimer’s Vaccine to Begin Human Trials
This clinical trial takes place nearly 20 years after the investigation began. The goal is to prevent and delay the disease.
The innovative nasal vaccine against Alzheimer’s will start with tests in humans. The study starts with 16 participants, between 60 and 85 years, all with some symptoms of the disease. The treatment comes nearly 20 years after the start of the investigation by Howard L. Weiner, director of the Ann Romney Center for Neurologic Diseases, a hospital in Boston, in the United States of America.
The two doses of vaccine will be given one week apart. If the trial goes well, another one will have to be done on a larger scale, in order to prove the efficacy of the drug. In this treatment a substance that stimulates the immune system is used.
“Protolin was designed to activate the white blood cells found in lymph nodes on the sides and back of the neck, then migrate to the brain and trigger the removal of beta amyloid plaques. [uma das marcas distintivas da doença de Alzheimer]”, explains the hospital to CBS News.
The institution believes that this is an important step in defining future therapy for the disease.. “It is exciting that after two decades of preclinical work, we are finally able to take a fundamental step into clinical practice and conduct the first human trial of this milestone in medicine.”